Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

Autor: Smith, Matthew R., Shore, Neal, Tammela, Teuvo L., Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Le Berre, Marie-Aude, Mohamed, Ateesha F., Odom, Dawn, Bartsch, Jennifer, Snapir, Amir, Sarapohja, Toni, Fizazi, Karim

Publikováno v: In European Journal of Cancer September 2021 154:138-146

Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac

Autor: Mladsi, Deirdre, Ronquest, Naoko, Odom, Dawn, Miles, LaStella, Saag, Kenneth

Publikováno v: In Clinical Therapeutics November 2016 38(11):2418-2429

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial

Autor: Schjesvold, Fredrik H, Goldschmidt, Hartmut, Maisnar, Vladimir, Spicka, Ivan, Abildgaard, Niels, Rowlings, Philip, Cain, Lauren, Romanus, Dorothy, Suryanarayan, Kaveri, Rajkumar, Vincent, Odom, Dawn, Gnanasakthy, Ari, Dimopoulos, Meletios A.

Publikováno v: Schjesvold, Fredrik H Goldschmidt, Hartmut Maisnar, Vladimir Spicka, Ivan Abildgaard, Niels Rowlings, Philip Cain, Lauren Romanus, Dorothy Suryanarayan, Kaveri Rajkumar, Vincent Odom, Dawn Gnanasakthy, Ari Dimopoulos, Meletios A. . Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. European Jo
European Jo

Externí odkaz: http://hdl.handle.net/10852/83471
https://www.duo.uio.no/bitstream/handle/10852/83471/1/Quality%2Bof%2Blife%2Bis%2Bmaintained%2Bwith%2Bixazombi%2Bmaintenance%2Bin%2Bpost%2Btransplant%2Bnewly%2Bdiagnosed%2Bmultiple%2Bmyeloma.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.